Abstract
Purpose
To investigate the feasibility and efficacy of curettage with hysteroscopy followed by megestrol acetate (MA) for well-differentiated endometrioid carcinoma (EC) confined to the endometrium and for atypical hyperplasia (AH) in young women.
Patients and methods
Fourteen patients with EC and 12 patients with AH were prospectively enrolled in this study. All of the patients received at least 12 weeks of oral MA (160 mg/day) following thorough curettage with hysteroscopy. The response was assessed histologically every 12 weeks. The primary endpoint was the complete response rate. Adverse events, pregnancy rates and recurrence rates were secondary end points.
Results
Twenty-one (80.8 %) patients responded to treatment. The median time to response was 12 weeks. After a median follow-up of 32 months, 6 patients had recurrences. Significantly, more patients with infertility or PCOS experienced recurrence (P = 0.040, P = 0.015). Eight patients attempted to conceive after complete response; two spontaneous conceptions and one normal delivery were achieved. No disease-related or treatment-related deaths were observed.
Conclusions
Fertility-sparing treatment with MA following entirely hysteroscopic curettage is effective, demonstrating the least toxicity for rigorously selected young women with well-differentiated EC confined to the endometrium or with AH; however, close follow-up is required for the potential consequences of improper patient selection and a substantial rate of recurrence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gallup DG, Stock RJ (1984) Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64:417–420
Emons G, Heyl W (2000) Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol 126:619–623
Erkanli S, Ayhan A (2010) Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 20:1170–1187
Signorelli M, Caspani G, Bonazzi C et al (2009) Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 116:114–118
Tangjitgamol S, Manusirivithaya S, Hanprasertpong J (2009) Fertility-sparing in endometrial cancer. Gynecol Obstet Invest 67:250–268
Chiva L, Lapuente F, Gonzalez-Cortijo L et al (2008) Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 111:S101–S104
Ushijima K, Yahata H, Yoshikawa H et al (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25:2798–2803
Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95:133–138
Kesterson JP, Fanning J (2012) Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. J Gynecol Oncol 23:120–124
Gunderson CC, Fader AN, Carson KA, Bristow RE (2012) Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: a systematic review. Gynecol Oncol 125:477–482
Koskas M, Yazbeck C, Walker F et al (2011) Fertility-sparing management of grade 2 and 3 endometrial adenocarcinomas. Anticancer Res 31:3047–3049
Laurelli G, Di Vagno G, Scaffa C et al (2011) Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol 120:43–46
Kim MK, Yoon BS, Park H et al (2011) Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer 21:673–677
Minig L, Franchi D, Boveri S et al (2011) Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 22:643–649
Fujiwara H, Jobo T, Takei Y et al (2012) Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. Oncol Lett 3:1002–1006
Koskas M, Azria E, Walker F et al (2012) Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res 32:1037–1043
Penner KR, Dorigo O, Aoyama C et al (2012) Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol 124:542–548
Dursun P, Erkanli S, Guzel AB et al (2012) A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer. Int J Gynaecol Obstet 119:270–273
Park H, Seok JM, Yoon BS et al (2012) Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Arch Gynecol Obstet 285:473–478
Park JY, Kim DY, Kim JH et al (2013) Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 49:868–874
Yamazawa K, Hirai M, Fujito A et al (2007) Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22:1953–1958
Wang CB, Wang CJ, Huang HJ et al (2002) Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 94:2192–2198
Thigpen JT, Brady MF, Alvarez RD et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736–1744
Ingram SS, Rosenman J, Heath R et al (1989) The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 17:21–27
Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158:796–807
Eftekhar Z, Izadi-Mood N, Yarandi F et al (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19:249–252
Mazzon I, Corrado G, Masciullo V et al (2010) Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 93:1286–1289
Palomba S, Falbo A, Zullo F, Orio FJ (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30:1–50
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shan, Be., Ren, Yl., Sun, Jm. et al. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet 288, 1115–1123 (2013). https://doi.org/10.1007/s00404-013-2826-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-013-2826-8